Probing Lactate Dehydrogenase Activity in Tumors by Measuring Hydrogen/Deuterium Exchange in Hyperpolarized L-[1-13C,U-2H]Lactate

Brett W. C. Kennedy, Mikko I. Kettunen, De-En Hu, and Kevin M. Brindle*

Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1GA, United Kingdom, and Cancer Research UK Cambridge Research Institute (CRI), Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, United Kingdom

ABSTRACT: 13C magnetic resonance spectroscopy and spectroscopic imaging measurements of hyperpolarized 13C label exchange between exogenously administered [1-13C]-pyruvate and endogenous lactate, catalyzed by lactate dehydrogenase (LDH), has proved to be a powerful approach for probing tissue metabolism in vivo. This experiment has clinical potential, particularly in oncology, where it could be used to assess tumor grade and response to treatment. A limitation of the method is that pyruvate must be administered in vivo at supra-physiological concentrations. This problem can be avoided by using hyperpolarized [1-13C]lactate, which can be used at physiological concentrations. However, sensitivity is limited in this case by the relatively small pyruvate pool size, which would result in only low levels of labeled pyruvate being observed even if there was complete label equilibration between the lactate and pyruvate pools. We demonstrate here a more sensitive method in which a doubly labeled lactate species can be used to measure LDH-catalyzed exchange in vivo. In this experiment exchange of the C2 deuterium label between injected hyperpolarized L-[1-13C,U-2H]lactate and endogenous unlabeled lactate is observed indirectly by monitoring phase modulation of the spin-coupled hyperpolarized 13C signal in a heteronuclear 1H/13C spin−echo experiment.

INTRODUCTION

Dynamic nuclear polarization (DNP) of 13C-labeled cell substrates, which enhances their sensitivity to detection in vivo by over 10,000-fold, has shown considerable promise for metabolic imaging in vivo, particularly in the field of cancer.1,2 The most widely used substrate to date has been hyperpolarized [1,13C]pyruvate, which has been used for early noninvasive detection of tumor response to drug treatment3,4 and assessment of tumor grade.5 Intravenous injection of hyperpolarized [1-13C]pyruvate results in exchange of the hyperpolarized 13C label with endogenous lactate in the reaction catalyzed by lactate dehydrogenase (E.C. 1.1.1.27) (LDH). Although there will be some net conversion of the injected pyruvate into lactate, the equilibrium constant for the reaction is such that chemical near-equilibrium is achieved with only a small net conversion of pyruvate into lactate (see Supporting Information in ref 3), which is then followed by exchange of the hyperpolarized 13C label between the steady-state near-equilibrium pyruvate and lactate pools. The evidence that this is an exchange reaction, which is discussed in ref 2 is summarized in the following. LDH has long been known to catalyze a reaction that is near-to-equilibrium in the cell.6 Addition of exogenous lactate has been shown to increase the isotope exchange velocity between pyruvate and lactate, increasing the detectable 13C label in the lactate pool.6 This is incompatible with net flux, where addition of lactate would result in product inhibition and a decrease in the rate of lactate labeling, but is consistent with isotope exchange, where the resulting increase in the near-equilibrium NADH concentration stimulates the exchange velocity of the enzyme.7 The exchange has been demonstrated directly in tumor cell suspensions by using [3-13C]pyruvate and unlabeled lactate and detecting the presence of the 13C label in the methyl group via splitting of the methyl proton resonance due to 13C−1H spin−spin coupling. The total pyruvate pool size remained relatively constant, while there was a decrease in the concentration of the 13C-labeled species and an increase in the 12C-labeled species. There were nearly reciprocal changes in the concentrations of the 12C- and 13C-labeled lactate species (see Supporting Information in 3). Exchange has also been demonstrated in vivo using magnetization transfer experiments in tumors displaying signals from hyperpolarized [1,13C]pyruvate and lactate following injection of a tumor-bearing animal with hyperpolarized [1-13C]pyruvate. Inversion of the lactate signal resulted in an increased rate of decay of the pyruvate resonance, demonstrating flux of hyperpolarized 13C label from lactate into the pyruvate pool.8 Recognizing that this is an exchange reaction explains observations made in vivo with hyperpolarized [1-13C]pyruvate. Thus, tumors show relatively high levels of lactate labeling since they tend to have large endogenous lactate pools, which provides a large pool for the label to exchange into and also increases the rate of the LDH-catalyzed reaction by increasing the NADH concentration.7 Tumors also express high levels of...
LDH-A, whose expression can be further increased by tumor hypoxia. These correlations with LDH-A activity and lactate pool size can explain why lactate labeling is correlated with tumor grade. Decreases in LDH activity and lactate and NAD(H) concentrations post-therapy also explain why measurements of the kinetics of lactate labeling following injection of hyperpolarized [1-13C]pyruvate can be used to assess early treatment response in tumors.

A potential limitation of the hyperpolarized [1-13C]pyruvate experiment is that pyruvate is injected at supra-physiological concentrations. In preclinical studies pyruvate has been injected at a whole blood concentration of ∼8 mM, assuming a mouse blood volume of 95 mL/kg, whereas the physiological plasma pyruvate concentration is ∼0.2 mM. In the first clinical trial of hyperpolarized [1-13C]pyruvate, where the aim was to use it to detect treatment response in prostate cancer, pyruvate has been injected at 0.43 mM/kg of a 250 mM solution (ClinicalTrials.gov Identifier: NCT01229618), which equates to a whole blood concentration of ∼1.5 mM, assuming a blood volume of 70 mL/kg. Although there has been no evidence of toxicity at these pyruvate concentrations, which is probably because the pyruvate clears quickly from the circulation, it would nevertheless be desirable to administer the labeled substrate at concentrations that are within the physiological range. Lactate is present in mouse plasma at concentrations that are within the physiological range. Lactate is present in mouse plasma at concentrations that are within the physiological range.

In human blood from fasted individuals has been measured at 0.061 ± 0.024 mM. Although there has been no evidence of toxicity at these pyruvate concentrations, which is probably because the pyruvate clears quickly from the circulation, it would nevertheless be desirable to administer the labeled substrate at concentrations that are within the physiological range. Lactate is present in mouse plasma at concentrations that are within the physiological range.

The deuterated lactate species were prepared as described previously for L-[2-13C3-2H3]- and L-[U-2H]-lactate. Briefly, 1 g sodium L-[1-13C1]-lactate (CIL, Massachusetts, USA or Sigma Aldrich, Gillingham, UK) was added to 4970 μL of 13C/D2O containing 0.1 M sodium phosphate buffer (pH 7.8), 3 mM LiOD in D2O; 600 mg (0.9 mmol) NAD+ (lithium salt), lactate dehydrogenase (1 kU; rabbit muscle, Sigma Aldrich, Gillingham, UK) and lipoyamide dehydrogenase (75 U, pig heart, Calzyme, San Luis Obispo, CA, USA). The mixture was incubated at 37 °C in the dark for 2 weeks, by which time >97% of the C2 protons had exchanged for deuterons (by comparison of the 13C and 2H NMR integrals in fully relaxed spectra). The mixture was heated to 100 °C for 10 min and the precipitated protein removed by filtration through a 0.22 μm pore size membrane. To the filtrate, 0.15 g (1.7 mmol) [1-13C]pyruvic acid (CIL, Massachusetts, USA) was added with enough disodium phosphate to increase the phosphate concentration to 200 mM. The pH was raised to 7.7 with 9% w/w LiOD in D2O; 600 mg (0.9 mmol) NAD+ (lithium salt) and 1 kU of lactate dehydrogenase and glutamate–pyruvate transaminase (Roche, Burgess Hill, UK) were added. The mixture was incubated at 37 °C in the dark for 2 weeks, after which time >96% of the C3 protons had exchanged for deuterons. For the preparation of L-[1-13C3-2H3]-lactate, sodium L-[1-13C1]-lactate was incubated in this latter mixture.

The zinc salt of lactate was obtained by acidification of the solution with 32% HCl, followed by neutralization with basic zinc carbonate. The resulting zinc lactate was purified by recrystallization from water/ethanol. The sodium salt was prepared using an ion-exchange resin (Dowex 50WX8, Na+ form) and then lyophilized. The lactate concentration was determined by enzymatic assay and by 1H and 13C NMR spectroscopy. The lactate purity was ≥99%, and the yield was 73% for perdeuterated lactate and 75% for the [1-13C3-2H3]-lactate. NMR Spectroscopy in Vitro. Experiments were performed at 9.4 T using a vertical bore magnet (Oxford Instruments) interfaced to a Varian Unova Inova console (Palo Alto) and a 10 mm 13C/1H probe. A 13C/1H heteronuclear spin–echo experiment was used with a 4 ms adiabatic 1H BIR4 180° refocusing pulse followed immediately by a 10 ms hyperbolic secant (R = 10°) 1H inversion pulse with the power adjusted either to zero or optimized to provide adiabatic inversion (Figure 2). The excitation profile of the 1H pulse was centered at 1.41 ppm, in order to selectively invert the C3 resonance without disturbing the C3 resonance at 1.33 ppm. The experiment was also performed with the 1H excitation profile centered at 1.33 ppm. A series of spectra, with echo times varying between 50 and 600 ms, were acquired into 2048 complex points with an 8 kHz spectral width and a repetition time of 180 s. The 13C T1s and T2s were measured at thermal equilibrium using inversion recovery and Carr–Purcell–Meiboom–Gill pulse sequences respectively.

Hyperpolarization of L-[1-13C1]-, L-[1-13C1-2-1H,3-2H3]-, and L-[1-13C1-3-2H]-lactate and [1-13C1-2H]-pyruvate. To aqueous solutions of L-[1-13C1]-, L-[1-13C1-2-1H,3-2H3]-, or L-[1-13C1-3-2H]-lactate (∼50% w/v) were added trityl radical (OX063; GE Healthcare, Amersham, UK) and gadolinium chelate (Dotarem; Guerbet, Roissy, France) to final concentrations of 15 mM and 1.2 mM, respectively. DMSO, to a final concentration of 30% w/v, was present in order to ensure glass formation in the solid state. [1-13C]Pyruvic acid samples (44 mg) contained 15 mM trityl radical and 1.4 mM of a gadolinium chelate (Dotarem). Samples were hyperpolarized as described previously. Briefly, the sample was frozen rapidly under liquid helium at 3.35 T in an alpha-prototype hyperpolarizer (GE Healthcare Plc, Amersham, UK) at a pressure of ~1 mbar (~1.2 K). Polarization was transferred to the 13C nuclei with irradiation at 93.965 GHz (100 mW).
over 90 min for lactate and 45 min for pyruvate. For both substrates the levels of polarization were typically greater than 20%. Lactate samples were dissolved in 4 mL PBS at 180 °C and 10 bar to give a concentration of 60 mM and pyruvate samples were dissolved in 6 mL of HEPES buffer (40 mM HEPES, 94 mM NaOH, 30 mM NaCl and 100 mg/L EDTA) at 180 °C and 10 bar to give a concentration of 75 mM. The samples were cooled before 0.2 mL was injected within 10 s either into a 10 mm NMR tube or into a C57BL/6 mouse via a tail-vein catheter.

**Figure 2.** $^{13}$C/$^1$H Heteronuclear spin–echo experiment with $^{[1-13C]}$lactate and $^{[1-13C,U-2H]}$lactate at thermal equilibrium. Signal intensity is plotted versus echo time (TE). Frequency-selective 180° $^1$H pulses were applied at 4.11 ppm and at 1.33 ppm.

**Tumor Experiments.** Female C57BL/6 mice ($n = 4, 6–8$ weeks of age; Charles River Ltd., Margate, UK) were injected subcutaneously in the lower flank with $5 \times 10^6$ EL-4 cells (EL-4 is a murine lymphoma cell line). At this location there was no detectable respiratory motion in MR images. MRS was performed when the tumors had grown to a size of $\sim 2$ cm$^3$ (which was reached typically at 10 days following implantation). $^1$H of the animals was treated with an intraperitoneal injection of 67 mg etoposide (PCH Pharmachemie BV) per kg body weight 24 h after the first MRS experiment, and the MRS measurement was repeated 24 h after treatment. For MRS experiments, animals were anesthetized with an intraperitoneal injection of Hypnorm (VetaPharma, Leeds, UK)/Hypnovel (Roche, Welwyn Garden City, UK)/dextrose–saline (4%:0.18%) in a 5:4:31 ratio (10 mL/kg body weight), and a catheter was inserted into the tail vein for injection of hyperpolarized lactate or pyruvate. The body temperature of the animals was maintained by blowing warm air through the magnet bore. All experiments were conducted in compliance with a project license and personal licenses issued under the Animals (Scientific Procedures) Act of 1986 and were designed with reference to the United Kingdom Co-ordinating Committee on Cancer Research guidelines for the welfare of animals in experimental neoplasia. The work was approved by a local ethical review committee.

**MR Spectroscopy in Vivo.** Experiments were performed using a 9.4 T vertical bore magnet (Oxford Instruments) interfaced to a Varian Unity console (Palo Alto). A $^{13}$C-surface coil (diameter 24 mm) was placed directly over the tumor, and the animal holder was then placed inside a $^1$H volume coil (Millipede, Varian Inc., length 6 cm, diameter 4 cm). Transverse $^1$H scout images were acquired using a gradient-echo pulse sequence (30° pulse; repetition time (TR), 300 ms; echo time (TE), 2.2 ms; field-of-view (FOV) 35 mm × 35 mm in a data matrix of 256 × 256 with two averages per increment; slice thickness 2 mm and 21 transverse slices). $^{13}$C Data collection was started 8 s after the beginning of a 200 μL i.v. injection of either 60 mM hyperpolarized $^{[1-^{13}C,U-2H]}$lactate or $^{[1-^{13}C]}$lactate or 75 mM hyperpolarized $^{[1-^{13}C]}$pyruvate and was continued for 75 s. Spectra were acquired, in the case of pyruvate, using a nominal flip angle of 10° at intervals of 1 s and in the case of lactate using a heteronuclear $^{13}$C/$^1$H spin–echo experiment which consisted of pairs of spin–echo spectra, echo time 310 ms, collected with and without an
1H inversion pulse (H+/H−) with a 500 ms delay between the low flip angle pulse of each member of the pair and a 5.5 s delay between the pairs. The spin–echo pulse sequence consisted of a nonselective 13C excitation pulse, with a 10° nominal flip angle, a 4 ms adiabatic 13C BIR4 180° refocusing pulse, followed immediately by a 10 ms hyperbolic secant (R = 10) 1H inversion pulse centered at 4.11 ppm with the power adjusted either to 0 (H−) or optimized to provide adiabatic inversion (H+) (Figure 2). The phase of the excitation pulse was changed by 180° for the second member of each echo pair to take account for inversion of the remaining longitudinal magnetization following the previous 13C refocusing pulse. Crusher gradients (5 G/cm, 2.5 ms) were placed around the refocusing pulses to destroy unwanted apparent T1 relaxation following the excitation pulse in the spin–echo experiment. The effect of RF pulses and T1 relaxation on the polarization were minimized and consequently ignored in this analysis. For perdeuterated lactate (L-[1-13C,U-2H]-lactate) this model can be written as:

\[
EF_I \rightarrow EF_{DL} \rightarrow \frac{k_{DH}}{k_{HD}} EF_{HL}
\]

where \(k_{EF}\) represents the inflow term and \(EF_{DL}\) and \(EF_{HL}\) represent respectively the detected C2-deuterated and C2-protonated lactate within the tumor. The differential equations for this system can be written in matrix form as:

\[
\begin{bmatrix}
EF_{DL} \\
EF_{HL}
\end{bmatrix}
= \left[
\begin{bmatrix}
-k_{DH} & k_{HD} \\
0 & 0 & -k_{eff}
\end{bmatrix}
\right]
\begin{bmatrix}
EF_{DL} \\
EF_{HL}
\end{bmatrix}
\]

The measured values of \(EF_{DL}\) and \(EF_{HL}\) were fitted to the model to obtain the exchange rate constants \(k_{DID}, k_{HD}\) and the inflow term \(k_{EF}\).

### RESULTS AND DISCUSSION

The 13C–1H J coupling constants between the C1 carbon and the C2 proton and between the C1 carbon and the C3 protons in lactate have been reported as 3.3 and 4.1 Hz, respectively.21

These were confirmed from spectra of L-[1-13C1]lactate (Figure 1) and L-[1-13C1,2-2H]lactate (data not shown). In a heteronuclear 13C/1H spin–echo experiment with L-[1-13C1]-lactate at thermal equilibrium, inversion of the 13C signal is observed at an echo time (TE) of 20–310 ms (1/\(J_{13C,2H}\)) when a selective 180° proton pulse is applied at the resonant frequency of the C2 proton (4.11 ppm), whereas no inversion is observed with L-[1-13C1,U-2H]-lactate (Figure 2). Thus, by taking advantage of the relatively slow 13C spin–spin relaxation rate (\(R_2\)), the presence of a deuterium label at the C2 position of lactate, which cannot be observed directly in the relatively poorly resolved 13C spectra obtained in vivo (Figure 3), can readily be detected from phase inversion of the spin-coupled C1 13C resonance in the spin–echo experiment. The effect of J coupling between the C1 carbon and the C3 protons is observed at TE ≅ 250 ms (1/\(J_{13C,3C}\)), where application of a selective 180° proton pulse at the resonant frequency of the C3 methyl protons (1.33 ppm) results in phase inversion of the C1 13C resonance (Figure 1B). The effect of this coupling between the C1 carbon and the C3 protons was observed in experiments performed in vivo by using perdeuterated lactate ([13C,13C,2H]lactate), which also removed the requirement for frequency-selective proton pulses.

Injection of hyperpolarized [1-13C]-lactate into an EL4-tumor-bearing mouse resulted in a low level of detectable [1-13C]pyruvate (Figure 3a), which peaked at 2% of the total
observable $^{13}$C signal (Figure 3b). Fitting of the lactate and pyruvate peak intensities to a two-site exchange model$^3$ gave a rate constant for flux of label from lactate to pyruvate of $0.0009 \pm 0.0005$ s$^{-1}$. Contrast this with experiments with hyperpolarized $[1-^{13}$C$]$pyruvate where, for much of the exchange time course, the lactate peak intensity exceeded that of pyruvate (Figure 3c,d). Fitting of these data gave a rate constant for the exchange of $0.056$ s$^{-1}$, which is comparable to values measured previously in this tumor model.$^3,22$

Figure 4a shows the Fourier transformed FID (Figure 4a (i)) and echo signals (Figure 4a (ii)) obtained from an EL4 tumor following injection of L-$[1-^{13}$C$]$lactate into a tumor-bearing mouse, where the FID was measured immediately following the low flip angle pulse in a heteronuclear $^{13}$C/$^1$H spin–echo experiment, and the echo was measured at 310 ms. Alternate echoes were acquired with a 180° $^1$H pulse, which resulted in nearly complete phase inversion of the spin-coupled hyperpolarized $^{13}$C resonance (Figure 4a (ii) and c). The average ratio of the echo signals obtained with and without the 180° $^1$H pulse (H$_+/H_-$) for each echo pair (see Methods section) was $86 \pm 7\%$ when the loss of polarization between the pair of echoes was ignored and $92 \pm 7\%$ when the echo signals were first corrected for this loss of polarization using the FID intensities obtained after each low flip angle pulse in the echo pair. Conversion of the echo intensities obtained with and without the 180° $^1$H pulse (H$_+/H_-$), using eqs 1 and 2, into the concentrations of the C2-deuterated and C2-protonated lactate species gave, due to imperfect phase inversion, an artificial baseline for $[1-^{13}$C,2-$^2$H$]$lactate of $\sim 10\%$, when of course there was no deuterated lactate present (Figure 4e). This low but artifactual baseline remained constant throughout the experiment (Figure 4g). In contrast, when L-$[1-^{13}$C, U-$^2$H$]$lactate was injected, there was initially little change in the hyperpolarized C$_1$ $^{13}$C resonance following application of a 180° $^1$H pulse; however, as exchange of the C2 deuterium with C2 protons in the endogenous lactate pool proceeded, the 180° $^1$H pulse resulted in a progressively larger decrease in the $^{13}$C resonance intensity (Figure 4d). Conversion of these signal intensities into the concentrations of the C2-deuterated ([1-$^{13}$C$_1$,U-$^2$H$_3$]) and C2-protonated ([1-$^{13}$C$_1$,2-$^2$H$_3$,3-$^2$H$_3$]) lactate species, using eqs 1 and 2, showed an increasing signal from the C2-protonated species during the exchange time course (Figure 4f,h). The exchange rate constants calculated using eq 5 are summarized in Table 1. Correction for the artifactual baseline, due to imperfect phase inversion, had only a modest effect on the fitted values (eqs 3 and 4). The relative decrease in label flux after etoposide treatment was similar to that observed previously with $[1-^{13}$C$]$pyruvate in this tumor model.$^3,22$ The calculated relaxation rate ($R_1$) from these three experiments was $0.037 \pm 0.005$ s$^{-1}$ ($n = 3$) (Table 2).

The ratio of the FID intensity to the intensity of the echo decreased substantially such that by 45 s after lactate injection the amplitudes of the echo and FID were comparable...
Figures 4 c,d), indicating that at later time points we were detecting a single lactate pool with relatively long $T_2$. $T_2$ measurements at $\sim 80$ s postinjection gave an apparent $T_2$ relaxation time of $0.605 \pm 0.013$ s ($n = 2$). In a previous study in this tumor model, where we injected hyperpolarized $[1-^{13}\text{C}]$pyruvate, we observed two $T_2$ components for pyruvate;
a short component (0.12 ± 0.02 s, 46 ± 14% of total signal) and a longer component (0.54 ± 0.16 s, 62 ± 22% of total signal), where these measurements were made much earlier after injection (15 − 30 s). An interpretation of these results is that the short T2 component represents the blood pool, which has an apparently short T2 because of flow effects, and therefore that the relative increase in lactate echo amplitude observed here was due to inflow of lactate from the blood pool into the tumor extravascular space. Note that the T1’s determined from the echo intensities are longer than those determined from the FID intensities (Table 2), which is also consistent with this notion. Note also that these changes in T2 had only a small effect on the degree of peak inversion since changing the sequence of the 180° 1H pulses (H+/H− or H−/H+) had no effect on the measured exchange kinetics, as would be expected from the relatively short echo spacing.

Reanalysis of the data shown in Figure 4 using the ratio of the FID intensity to the intensity of the echo (echo/FID ratio; EF) confirmed that this ratio increased over the exchange time course (Figure 4a,b). The concentrations of the different lactate species can be calculated from the EF ratios using eqs 1 and 2 and substituting for kDH, kHS, kH2, and kH2O with the corresponding EF ratios. When this analysis was used for the case where C2-protonated lactate was injected (L-[1-13C1,3-2H3]lactate; Figure 5c), a progressive increase in the signal intensity due to the C2-protonated lactate (L-[1-13C1,3-2H3]lactate; Figure 5d) were fitted to eq 9 to obtain the exchange rate constants and a term representing lactate inflow (Table 1). As noted for Figure 4e,g, the apparent production of C2-deuterated lactate following injection of C2-protonated lactate is due to imperfect phase inversion. Deconvolution of the effects of flow, membrane transport, and LDH kinetics on the observed exchange will require measurements where the levels of the transporter or LDH have been modulated, for example by changing LDH expression using a PI3K inhibitor.

The relaxation rates (R1, R2) for the polarization in the various lactate species, which were determined using pulse and acquire spectra and also from the FID and echo intensities in the heteronuclear spin−echo experiment, are shown in Table 2. The R1 relaxation rates calculated from the spin−echo experiments were faster than those calculated from the pulse and acquire spectra. This presumably reflects imperfections in the 13C refocusing pulses, which were delivered using a surface coil, leading to an accelerated loss of z magnetization. However, FID intensities within each echo pair were similar (Figure 4c,d), showing that there was only minor loss of z magnetization between each echo pair.

The sensitivity of this experiment, in which tumor LDH activity was assessed by measuring exchange of the C2 deuterium with protons in endogenous lactate, was lower than that in which exchange was measured directly between [1-13C]pyruvate and endogenous lactate (Figure 3c,d) but exceeded that when exchange was measured between [1-13C]-lactate and endogenous pyruvate (Figure 3a,b). Consider the signal intensities at 10 s following injection, when the concentration of labeled lactate was at a maximum following injection of hyperpolarized [1-13C]pyruvate (Figure 3d). At this time point the lactate signal was ∼50% of the injected pyruvate signal intensity (Figure 3d). At the same time point in the experiment with [1-13C3,2H2]lactate the echo intensity was ∼40% of the signal obtained immediately after the low flip angle pulse, due to T2 relaxation. Of this signal ∼20% was due to the C2-protonated lactate (L-[1-13C3,3-2H3]lactate; Figure 4f), or ∼10% of the lactate signal that was observed immediately after the low flip angle pulse. Contrast this with the experiment where exchange was measured between L-[1-13C]lactate and endogenous pyruvate, where the pyruvate signal was only ∼2% of the signal from injected lactate (Figure 3b).

**Table 2. Apparent Spin−Lattice (R1) and Spin−Spin (R2) Relaxation Rates for the Different Labeled Lactate Species in Vitro and in a Tumor in Vivo**

| Species                        | R1 (s−1)       | R2 (s−1)       |
|-------------------------------|----------------|----------------|
| L-[1-13C,U-2H]lactate         |                |                |
| in vitro                      | 0.021 ± 0.002  | 0.023 ± 0.005  |
| in vivo, pulse-acquire         | 0.023          | 0.025          |
| in vivo, spin−echo (FID)       | 0.047 ± 0.002  | 0.042          |
| in vivo, spin−echo (echo)      | 0.037 ± 0.005  | 0.038          |
| L-[1-13C3,U-2H]lactate        |                |                |
| in vitro                      | 0.75 ± 0.06    | 0.67 ± 0.06 n = 4 |

*Measured with non-hyperpolarized samples of 30 mM lactate at 37 °C in phosphate-buffered saline, pH 7.1, 1 mM EDTA using an inversion−recovery pulse sequence. These values are from single measurements, and the quoted errors are on the fit. aMeasured with non-hyperpolarized samples of 10 mM lactate at 25 °C in 2H2O.*
CONCLUSIONS

We have described a new hyperpolarized substrate, L-[^1-13C,U-2H]lactate, in which measurements of exchange of the C2 deuterium with the C2 protons in endogenous lactate, in a hyperpolarized $^{13}$C/1H heteronuclear spin−echo experiment, can be used to probe LDH kinetics in vivo. This experiment has the advantage that it uses lactate, which can be injected at physiological concentrations, and is more sensitive than in the experiment in which exchange of the 13C label between lactate and pyruvate is measured, where the size of the endogenous pyruvate pool is a limiting factor. In addition, since only a single peak is observed, imaging will be more straightforward since chemical shift selection is not required. Furthermore, at the lower magnetic field strengths used in the clinic, the $T_2$ relaxation times should be longer, and therefore detection of the C2-protonated and C2-deuterated lactate species should be more sensitive.

AUTHOR INFORMATION

Corresponding Author
kmb1001@cam.ac.uk

ACKNOWLEDGMENTS

This work was supported by a Cancer Research UK Program Grant to K.M.B. (C197/A3514) and by a Translational Research Program Award from The Leukemia and Lymphoma Society. B.W.C.K. was in receipt of a Cancer Research UK studentship.

REFERENCES

(1) Kurhanewicz, J.; Vigneron, D.; Brindle, K.; Chekmenev, E.; Comment, A.; Cunningham, C.; DeBerardinis, R.; Green, G.; Leach, M.; Rajan, S.; Rizi, R.; Ross, B.; Warren, W.; Malloy, C. Neoplasia 2011, 13, 81−97.

(2) Brindle, K. M.; Bohndiek, S. E.; Gallagher, F. A.; Kettunen, M. I. Magn. Reson. Med. 2011, 66, 505−519.

(3) Day, S. E.; Kettunen, M. I.; Gallagher, F. A.; Hu, D. E.; Lerche, M.; Wolber, J.; Golman, K.; Ardenkjaer-Larsen, J. H.; Brindle, K. M. Nat. Med. 2007, 13, 1382−1387.

(4) Ward, C. S.; Venkatesh, H. S.; Chaumeil, M. M.; Brandes, A. H.; Vancriekinge, M.; Dafni, H.; Sukumar, S.; Nelson, S. J.; Vigneron, D. B.;...
Kurhanewicz, J.; James, C. D.; Haas-Kogan, D. A.; Ronen, S. M. Cancer Res. 2009, 70, 1296–1305.
(5) Albers, M. J.; Bok, R.; Chen, A. P.; Cunningham, C. H.; Zierhut, M. L.; Zhang, V. Y.; Kohler, S. J.; Tropp, J.; Hurd, R. E.; Yen, Y. F.; Nelson, S. J.; Vigneron, D. B.; Kurhanewicz, J. Cancer Res. 2008, 68, 8607–8615.
(6) Veech, R. L.; Lawson, J. W.; Cornell, N. W.; Krebs, H. A. J. Biol. Chem. 1979, 254, 6538–6547.
(7) Witney, T. H.; Kettunen, M. I.; Brindle, K. M. J. Biol. Chem. 2011, 286, 24572–24580.
(8) Kettunen, M. I.; Hu, D.-E.; Witney, T. H.; McLaughlin, R.; Gallagher, F. A.; Bohndiek, S. E.; Day, S. E.; Brindle, K. M. Magn. Reson. Med. 2010, 63, 872–880.
(9) Koukourakis, M. I.; Giatromanolaki, A.; Sivridis, E.; Bougioukas, G.; Didilis, V.; Gatter, K. C.; Harris, A. L. Br. J. Cancer 2003, 89, 877–885.
(10) Riches, A.; Sharp, J.; Brynmor Thomas, D.; Vaughan Smith, S. J. Physiol. 1973, 238, 279–284.
(11) Wu, C.; Okar, D. A.; Newgard, C. B.; Lange, A. J. Clin. Invest. 2001, 107, 91–98.
(12) Kelly, F.; Simonsen, D.; Elman, R. J. Clin. Invest. 1948, 27, 795–804.
(13) Marbach, E. P.; Weil, M. H. Clin. Chem. 1967, 13, 314–325.
(14) Hurley, B. F.; Hagberg, J. M.; Allen, W. K.; Seals, D. R.; Young, J. C.; Cuddihuee, R. W.; Holloszy, J. O. J. Appl. Physiol. 1984, 56, 1260–1264.
(15) Chen, A. P.; Kurhanewicz, J.; Bok, R.; Xu, D.; Joun, D.; Zhang, V.; Nelson, S. J.; Hurd, R. E.; Vigneron, D. B. Magn. Reson. Imaging 2008, 26, 721–726.
(16) Brindle, K. M.; Campbell, I. D.; Simpson, R. J. Eur. J. Biochem. 1986, 158, 299–305.
(17) Brindle, K. M.; Brown, F. F.; Campbell, I. D.; Foxall, D. L.; Simpson, R. J. Biochem. J. 1982, 202, 589–602.
(18) Brindle, K. M.; Brown, F. F.; Campbell, I. D.; Grathwohl, C.; Kuchel, P. W. Biochem. J. 1979, 180, 37–44.
(19) Hohorst, H. In Methods of Enzymatic Analysis; Bergmeyer, H. U., Ed.; Verlag Chemie: Weinheim, 1970; Vol. 2, pp 1425–1429.
(20) Tannus, A.; Garwood, M. J. Magn. Reson. Biomed. 1997, 10, 423–434.
(21) Chen, A. P.; Tropp, J.; Hurd, R. E.; Criekeinge, M. V.; Carvajal, L. G.; Xu, D.; Kurhanewicz, J.; Vigneron, D. B. J. Magn. Reson. 2009, 197, 100–106.
(22) Witney, T.; Kettunen, M.; Day, S.; Hu, D.; Neves, A.; Gallagher, F.; Fulton, S.; Brindle, K. Neoplasia 2009, 6, 574–582.